Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 150 participants.
Also called NCT00117936
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 150 participants
- Sponsor
- Venturis Therapeutics, Inc.
- Registry
-
NCT00117936
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT00117936. Randomized; double masking; primary purpose treatment. Start 2027-09-01 (anticipated); primary completion 2029-11-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease
- Condition
- Coronary Disease
- Condition
- Coronary Heart Disease
- Condition
- Myocardial Ischemia
- Condition
- Coronary Arteriosclerosis
- Intervention (Combination product)
- Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose
- Intervention (Combination product)
- Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose
- Intervention (Combination product)
- Placebo
- Lead sponsor
- Venturis Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct00117936- Content hash
452d602749a2a86760126516f579d1259db8774d17688d355d47d5809a52f51d